Suven Life receives product patents in Israel and Japan

Leading biopharma company, Suven Life Sciences Limited announced the grant of one product patent from Israel and one product patent from Japan new chemical compounds for the treatment of neurodegenerative diseases.

The issued claims of the patents are for class of selective M1 PAM and 5-HT4 compounds and are being developed as medications for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Huntington’s disease, Parkinson , ADHD and schizophrenia.

The company's pipeline of molecules in the CNS therapeutic area have high unmet potential, internationally. Suven Life Science has four clinical stage compounds in various phases.

On Tuesday, the stock of Suven Life Sciences was trading Rs. 245.35 per share, up by 1.91 per cent on BSE, while the benchmark index was at 34,991.91, up by 40.99 points or 0.12 per cent.